Breast Cancer Mortality Risks by Hormone Receptor Status
Author Information
Author(s): Dunnwald Lisa K, Rossing Mary Anne, Li Christopher I
Primary Institution: University of Washington
Hypothesis
Does the risk of breast cancer-specific mortality vary by hormone receptor status and demographic or clinical characteristics?
Conclusion
Women with ER+/PR-, ER-/PR+, or ER-/PR- tumors have higher mortality risks compared to those with ER+/PR+ tumors, regardless of demographic and clinical factors.
Supporting Evidence
- ER+/PR- cases had a 1.5-fold increased risk of mortality compared to ER+/PR+ cases.
- ER-/PR+ cases had a 2.1-fold increased risk of mortality compared to ER+/PR+ cases.
- ER-/PR- cases had a 2.6-fold increased risk of mortality compared to ER+/PR+ cases.
- Mortality risks increased with tumor size and grade across all ER/PR profiles.
- Older age at diagnosis was associated with higher mortality risks.
Takeaway
Women with certain types of breast cancer are more likely to die from it than others, especially if their tumors don't have certain hormone receptors.
Methodology
Data from 11 cancer registries were analyzed using the Cox proportional hazards model to evaluate mortality risks based on hormone receptor status.
Potential Biases
Potential biases due to missing ER/PR data and variations in testing methods across laboratories.
Limitations
The study relies on SEER data, which may have inconsistencies in ER/PR testing and lacks information on adjuvant therapies.
Participant Demographics
Women aged 30 and older, with a diverse racial/ethnic background.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 1.7 to 3.9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website